Case Report: Furmonertinib-induced acute interstitial lung disease

TL;DR

A 71-year-old woman developed severe lung disease after treatment with furmonertinib, a drug used for lung cancer, but recovered after early diagnosis and intervention.

Contribution

This is the first reported case of furmonertinib-induced interstitial lung disease, highlighting the importance of early recognition.

Findings

A patient developed acute interstitial lung disease while on furmonertinib therapy.

Early diagnosis and intervention led to a favorable clinical outcome.

The case suggests that furmonertinib can cause severe lung toxicity in rare instances.

Abstract

Furmonertinib is a third-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits EGFR-TKI-sensitive mutations. Although furmonertinib is generally well-tolerated and no severe drug-related interstitial lung disease (ILD) has been reported in the literature to date, we present a case of furmonertinib-induced ILD in a 71-year-old woman with EGFR-mutated lung adenocarcinoma (LUAD). On day 97 of treatment, the patient developed acute severe dyspnea, which rapidly progressed to diffuse bilateral lung consolidation and profound hypoxemia. After excluding other potential causes of interstitial pneumonia, a diagnosis of furmonertinib-related ILD was established. Through timely diagnosis and appropriate intervention, the patient achieved a favorable outcome. This case highlights that early recognition and management can reverse this serious adverse event and help preserve subsequent treatment options.

Figures